[Clopidogrel resistance--clinical significance, pathogenesis and potential solutions].

Elad Asher*, Hanoch Hod, Jonathan Buber, Roy Beigel, Ori Vatury, Shlomi Matetzky

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Platelet activation and aggregation play a major role in the pathogenesis of acute coronary syndrome (ACS) and thrombotic complications following percutaneous coronary interventions (PCI). Antiplatelet therapy with aspirin (ASA) and/or clopidogrel remains one of the most effective therapies for the treatment of ACS and prevention of thrombotic complications following PCI. Nevertheless, not all patients achieve the desired laboratory and/or clinical effect following antiplatelet therapy. These patients have been termed "aspirin resistant" or "clopidogrel resistant". In recent years, several studies regarding clopidogrel resistance have been conducted, and a number of pharmacological therapies, together with new treatments, have been suggested. This review aims to provide an overview of the epidemiology, prevalence, clinical significance and potential solutions regarding clopidogrel resistance.

Original languageEnglish
Pages (from-to)131-135, 206, 205
Issue number2
StatePublished - Feb 2011


Dive into the research topics of '[Clopidogrel resistance--clinical significance, pathogenesis and potential solutions].'. Together they form a unique fingerprint.

Cite this